BML-277 is a highly selective inhibitor of Chk2 (IC50=15nM). It displays potent radioprotective activity and prevents apoptosis of human T cells subjected to ionizing radiation (EC50= 3-7.6µM). Useful tool for dissecting the role of Chk2 in cellular signaling.
Product Details
| Alternative Name: | Chk2 Inhibitor II |
| |
| Formula: | C20H14ClN3O2 |
| |
| MW: | 363.8 |
| |
| CAS: | 516480-79-8 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Appearance: | Off-white solid. |
| |
| Solubility: | Soluble in DMSO (20mg/ml) or ethanol (20mg/ml). |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Dual roles of ERK1/2 in cellular senescence induced by excess thymidine in HeLa cells: I. Kudo, et al.; Exp. Cell. Res.
16, 30205 (2016),
Application(s): Cell culture, cervical tumor cells,
Abstract;
Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage: Y. Pereg, et al.; Mol. Cell. Biol.
26, 6819 (2006),
Abstract;
Full Text
Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles: K.L. Arienti, et al. ; J. Med. Chem.
48, 1873 (2005),
Abstract;
